Aeglea BioTherapeutics is in the process of developing an enzyme replacement therapy for patients with CBS Deficiency Homocystinuria.
For the most up-to-date news on their enzyme replacement, please visit their website: Click here
October 10, 2018
Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting
Positive Preclinical Efficacy Data on its AEB4104 Homocystinuria Therapeutic Program